RESULTS ROUND-UP: Abiomed, Roche, Stryker positive; Siemens must do better
This article was originally published in Clinica
As expected, the US FDA has approved Abiomed’s Impella RP percutaneous heart pump under a humanitarian device exemption for right-sided heart failure. The firm also reported 34% sales growth in its third fiscal quarter, at $62.0m, as worldwide Impella revenues shot up 37% to $57.4m. Jefferies analyst Raj Denhoy said it “could prove to be its breakout quarter. Revenues of $62m handily exceeded our $52m forecast.” He added: “The performance looks sustainable as the company is calling for 20% growth in FY16.”
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.